Stockscreener 앱 받기
3.915
16.84%
-0.775
전일 마감가:
$4.69
열려 있는:
$4.18
하루 거래량:
5.68M
Relative Volume:
20.38
시가총액:
$8.10M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-0.256
EPS:
-15.2954
순현금흐름:
$-24.23M
1주 성능:
-19.25%
1개월 성능:
-63.22%
6개월 성능:
-76.58%
1년 성능:
-91.61%
1일 변동 폭
$3.63
$4.2099
1주일 범위
$3.63
$5.32
52주 변동 폭
$3.63
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
MBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
3.915 | 9.71M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.64 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.39 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
872.32 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
390.58 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
201.83 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-09 | 재개 | H.C. Wainwright | Buy |
| 2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Moleculin Biotech Prepares for 1-for-25 Reverse Split Amidst Clinical Advancements - timothysykes.com
Moleculin Biotech shares slide after release of pediatric brain tumor trial data - MSN
Moleculin Biotech’s Bold Move: Stock Split Announced - StocksToTrade
Moleculin's WP1066 Shows Immune Activity, Favorable Safety In Pediatric Brain Cancer Trial - Nasdaq
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin announces positive phase 1 data for WP1066 in pediatric brain tumors - marketscreener.com
Moleculin Biotech’s Reverse Split Shocks Market - timothysykes.com
Moleculin Biotech stock falls after pediatric brain tumor trial results - Investing.com
Moleculin’s brain cancer drug shows promise in pediatric trial - Investing.com India
Moleculin Biotech Reports Positive Phase 1 Trial Results - TipRanks
Moleculin’s brain cancer drug shows promise in pediatric trial By Investing.com - Investing.com South Africa
Moleculin Biotech Reports Positive Phase 1 Trial Results for WP1066 in Pediatric Brain Cancer Treatments - Quiver Quantitative
Moleculin Biotech, Inc. Announces Positive Phase 1 Trial Results for WP1066 - TradingView — Track All Markets
Early trial in children finds brain tumor therapy sparks immune response - Stock Titan
Moleculin Biotech Regains Nasdaq Compliance - TipRanks
Moleculin Biotech regains compliance with Nasdaq minimum bid price rule - Investing.com India
Moleculin Biotech regains compliance with Nasdaq minimum bid price rule By Investing.com - Investing.com UK
Moleculin Biotech (MBRX) Target Price Adjusted by Roth Capital A - GuruFocus
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
CapEx per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView — Track All Markets
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech (MBRX) Sees Significant Price Target Upgrade - GuruFocus
HC Wainwright & Co. Maintains Moleculin Biotech (MBRX) Buy Recommendation - Nasdaq
Moleculin Biotech raises $6.5 million through warrant exercise By Investing.com - Investing.com Nigeria
Moleculin Biotech Enters Inducement Offer Agreements - TipRanks
Moleculin Biotech stock falls after warrant exercise agreement By Investing.com - Investing.com South Africa
Moleculin Biotech stock falls after warrant exercise agreement - Investing.com India
Moleculin Biotech raises $6.5 million through warrant exercise - Investing.com
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds - The Manila Times
Moleculin Biotech, Inc. Announces Immediate Exercise of Warrants for Gross Proceeds of Approximately $6.5 Million - Quiver Quantitative
Moleculin Biotech (Nasdaq: MBRX) enters warrant exercise deals for approx $6.5M - Stock Titan
Moleculin Biotech (MBRX) Stock: Faces Market Drop Despite Positive MIRACLE Trial Enrollment Progress - parameter.io
Moleculin Biotech (MBRX) Approaches Key Enrollment Milestone in Leukemia Study - GuruFocus
Moleculin Biotech Updates on MIRACLE Study Progress - TipRanks
Moleculin stock rises as AML trial enrollment reaches 78% By Investing.com - Investing.com Nigeria
Moleculin Biotech, Inc. Updates on MIRACLE Phase 2B/3 AML Trial Progress - TradingView — Track All Markets
Moleculin stock rises as AML trial enrollment reaches 78% - Investing.com
Moleculin reports 78% enrollment in AML treatment trial - Investing.com
Moleculin reports 78% enrollment in AML treatment trial By Investing.com - Investing.com South Africa
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal 'MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - The Manila Times
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - Sahm
Moleculin Announces Completion of Treatment for the 45 - GlobeNewswire
The MIRACLE Test: Trial Progress And Market Moves Put Moleculin In Focus - RTTNews
Moleculin (Nasdaq: MBRX) Tracks Toward 45-Patient MIRACLE AML Readout in Q1 2026 - Stock Titan
Moleculin enters research agreement for brain cancer treatment By Investing.com - Investing.com Australia
After tax other income/expense of Moleculin Biotech, Inc. – BER:MOL0 - TradingView — Track All Markets
Moleculin Biotech Partners with CIC biomaGUNE for Research - TipRanks
Moleculin Biotech (MBRX) Partners with CIC biomaGUNE for Brain C - GuruFocus
Moleculin enters research agreement for brain cancer treatment - Investing.com
Moleculin Announces New Annamycin Collaboration in Brain Tumors - The Manila Times
Moleculin Biotech, Inc. Partners with CIC biomaGUNE for Preclinical Research on Annamycin as a Treatment for Glioblastoma Multiforme - Quiver Quantitative
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Moleculin Biotech Inc 주식 (MBRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
0.12%
0.24%
자본화:
|
볼륨(24시간):